Results 91 to 100 of about 344,680 (247)
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells _in vitro_ and _in vivo_ [PDF]
, 2008 CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody (mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives _in ...
Benjamin Dä +20 more
core +1 more source
MULTIPLE MYELOMA. IV. ABNORMAL SERUM COMPONENTS AND BENCE JONES PROTEIN 1 [PDF]
, 1951 R. Wayne Rundles +2 more
openalex +1 more source
URETHANE (ETHYL CARBAMATE) THERAPY IN MULTIPLE MYELOMA [PDF]
, 1949 J. PHILIP LOGE, R. Wayne Rundles
openalex +1 more source
STUDIES IN SERUM ELECTROLYTES. XV. THE CALCIUM-BINDING PROPERTY OF THE SERUM PROTEINS (MULTIPLE MYELOMA, LYMPHOGRANULOMA VENEREUM AND SARCOIDOSIS) [PDF]
, 1948 Arnold J. Rawson, F. William Sunderman
openalex +1 more source
Role of minimal residual disease assessment in multiple myeloma
HaematologicaMultiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat +2 more
doaj +1 more source
Frontiers in ImmunologyPlasma cell disorders present challenges in phenotypic determination, as they range from monoclonality of plasma cells to multiple myeloma and plasma cell leukemia.
Mahmoud Singer +5 more
doaj +1 more source
Multiple Myeloma Treated with Stilbamidine and Pentamidine [PDF]
, 1948 A. E. Brewer
openalex +1 more source